Drug therapy and catheter ablation for atrill fibrillation

Research output: Contribution to journalArticle

Abstract

In all clinical trials comparing rate versus rhythm control of atrial fibrillation (AF) by drugs, there was no survival benefit associated with a rhythm control strategy. Currently used antiarrhythmic drugs are not only frequently ineffective at eliminating AF, but may be life threatening In some patients. Catheter ablation (CA) of AF has evolved rapidly and has become accepted as one of the therapeutic modalities for controlling AF. The effective strategies for CA of AF consist of pulmonary vein isolation (PVI) and/or complete encirclement around PVs with or without additional ablation lines. Selection of patients, who may be benefited by CA or not, Is an important Issue. Precise electroanatomic mapping for the triggers and the substrate of the atria is central for customizing ablation target and for enhancing efficacy of CA for AF. With further development of new energy sources of ablation, cardiac imaging, navigation, and mapping systems, the CA can be simplified and standardized, which may enable the CA to become more effective, safer, and more applicable to many different subsets of AF.

Original languageEnglish
Pages (from-to)317-326
Number of pages10
JournalJournal of the Korean Medical Association
Volume51
Issue number4
DOIs
Publication statusPublished - 2008 Apr 1

Fingerprint

Catheter Ablation
Atrial Fibrillation
Drug Therapy
Pulmonary Veins
Anti-Arrhythmia Agents
Patient Selection
Clinical Trials
Survival
Pharmaceutical Preparations

Keywords

  • Antiarrhythmic drugs
  • Atrial fibrillation
  • Catheter ablation
  • Mapping

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Drug therapy and catheter ablation for atrill fibrillation. / Kim, Young Hoon.

In: Journal of the Korean Medical Association, Vol. 51, No. 4, 01.04.2008, p. 317-326.

Research output: Contribution to journalArticle

@article{7c261c1cfa8d4d55b82172d54c53eee8,
title = "Drug therapy and catheter ablation for atrill fibrillation",
abstract = "In all clinical trials comparing rate versus rhythm control of atrial fibrillation (AF) by drugs, there was no survival benefit associated with a rhythm control strategy. Currently used antiarrhythmic drugs are not only frequently ineffective at eliminating AF, but may be life threatening In some patients. Catheter ablation (CA) of AF has evolved rapidly and has become accepted as one of the therapeutic modalities for controlling AF. The effective strategies for CA of AF consist of pulmonary vein isolation (PVI) and/or complete encirclement around PVs with or without additional ablation lines. Selection of patients, who may be benefited by CA or not, Is an important Issue. Precise electroanatomic mapping for the triggers and the substrate of the atria is central for customizing ablation target and for enhancing efficacy of CA for AF. With further development of new energy sources of ablation, cardiac imaging, navigation, and mapping systems, the CA can be simplified and standardized, which may enable the CA to become more effective, safer, and more applicable to many different subsets of AF.",
keywords = "Antiarrhythmic drugs, Atrial fibrillation, Catheter ablation, Mapping",
author = "Kim, {Young Hoon}",
year = "2008",
month = "4",
day = "1",
doi = "10.5124/jkma.2008.51.4.317",
language = "English",
volume = "51",
pages = "317--326",
journal = "Journal of the Korean Medical Association",
issn = "1975-8456",
publisher = "Korean Medical Association",
number = "4",

}

TY - JOUR

T1 - Drug therapy and catheter ablation for atrill fibrillation

AU - Kim, Young Hoon

PY - 2008/4/1

Y1 - 2008/4/1

N2 - In all clinical trials comparing rate versus rhythm control of atrial fibrillation (AF) by drugs, there was no survival benefit associated with a rhythm control strategy. Currently used antiarrhythmic drugs are not only frequently ineffective at eliminating AF, but may be life threatening In some patients. Catheter ablation (CA) of AF has evolved rapidly and has become accepted as one of the therapeutic modalities for controlling AF. The effective strategies for CA of AF consist of pulmonary vein isolation (PVI) and/or complete encirclement around PVs with or without additional ablation lines. Selection of patients, who may be benefited by CA or not, Is an important Issue. Precise electroanatomic mapping for the triggers and the substrate of the atria is central for customizing ablation target and for enhancing efficacy of CA for AF. With further development of new energy sources of ablation, cardiac imaging, navigation, and mapping systems, the CA can be simplified and standardized, which may enable the CA to become more effective, safer, and more applicable to many different subsets of AF.

AB - In all clinical trials comparing rate versus rhythm control of atrial fibrillation (AF) by drugs, there was no survival benefit associated with a rhythm control strategy. Currently used antiarrhythmic drugs are not only frequently ineffective at eliminating AF, but may be life threatening In some patients. Catheter ablation (CA) of AF has evolved rapidly and has become accepted as one of the therapeutic modalities for controlling AF. The effective strategies for CA of AF consist of pulmonary vein isolation (PVI) and/or complete encirclement around PVs with or without additional ablation lines. Selection of patients, who may be benefited by CA or not, Is an important Issue. Precise electroanatomic mapping for the triggers and the substrate of the atria is central for customizing ablation target and for enhancing efficacy of CA for AF. With further development of new energy sources of ablation, cardiac imaging, navigation, and mapping systems, the CA can be simplified and standardized, which may enable the CA to become more effective, safer, and more applicable to many different subsets of AF.

KW - Antiarrhythmic drugs

KW - Atrial fibrillation

KW - Catheter ablation

KW - Mapping

UR - http://www.scopus.com/inward/record.url?scp=78549244101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78549244101&partnerID=8YFLogxK

U2 - 10.5124/jkma.2008.51.4.317

DO - 10.5124/jkma.2008.51.4.317

M3 - Article

AN - SCOPUS:78549244101

VL - 51

SP - 317

EP - 326

JO - Journal of the Korean Medical Association

JF - Journal of the Korean Medical Association

SN - 1975-8456

IS - 4

ER -